NO325760B1 - Farmasoytisk preparat i fast enhetsdoseringsform - Google Patents

Farmasoytisk preparat i fast enhetsdoseringsform Download PDF

Info

Publication number: NO325760B1
Authority: NO; Norway
Prior art keywords: approx; preparation; microcrystalline cellulose; pregelatinized starch; weight
Prior art date: 1995-02-28

Application number

NO19973938A

Other languages

English (en)

Norwegian (no)

Other versions

NO973938D0 (no

NO973938L (no

Inventor

Paul F Skultety

Thomas T Ortyl

Kristen C Mitchell

Deepak S Phadke

Faraneh Attarchi

Margurite L Pierce

Aaron W Schoeneman

Joseph M Schnitz

Original Assignee

Aventis Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-02-28

Filing date

1997-08-27

Publication date

2008-07-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27015322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO325760(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-08-27 Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc

1997-08-27 Publication of NO973938D0 publication Critical patent/NO973938D0/no

1997-10-28 Publication of NO973938L publication Critical patent/NO973938L/no

2008-07-14 Publication of NO325760B1 publication Critical patent/NO325760B1/no

Links

239000000825 pharmaceutical preparation Substances 0.000 title claims description 24
239000007892 solid unit dosage form Substances 0.000 title claims description 12
239000000203 mixture Substances 0.000 claims description 136
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 117
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 90
150000001875 compounds Chemical class 0.000 claims description 90
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 62
238000000034 method Methods 0.000 claims description 59
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 47
229940016286 microcrystalline cellulose Drugs 0.000 claims description 47
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 47
239000008108 microcrystalline cellulose Substances 0.000 claims description 47
108010010803 Gelatin Proteins 0.000 claims description 41
229920000159 gelatin Polymers 0.000 claims description 41
239000008273 gelatin Substances 0.000 claims description 41
235000019322 gelatine Nutrition 0.000 claims description 41
235000011852 gelatine desserts Nutrition 0.000 claims description 41
229920000881 Modified starch Polymers 0.000 claims description 40
150000003839 salts Chemical class 0.000 claims description 39
229940014259 gelatin Drugs 0.000 claims description 34
235000019359 magnesium stearate Nutrition 0.000 claims description 31
229920002785 Croscarmellose sodium Polymers 0.000 claims description 29
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 29
229960001681 croscarmellose sodium Drugs 0.000 claims description 29
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 29
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 28
238000002360 preparation method Methods 0.000 claims description 27
238000002156 mixing Methods 0.000 claims description 26
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 21
239000008101 lactose Substances 0.000 claims description 21
229920003109 sodium starch glycolate Polymers 0.000 claims description 17
229940079832 sodium starch glycolate Drugs 0.000 claims description 17
239000008109 sodium starch glycolate Substances 0.000 claims description 17
229910000019 calcium carbonate Inorganic materials 0.000 claims description 14
239000002552 dosage form Substances 0.000 claims description 14
230000003287 optical effect Effects 0.000 claims description 14
239000007787 solid Substances 0.000 claims description 14
229960001375 lactose Drugs 0.000 claims description 10
229940057948 magnesium stearate Drugs 0.000 claims description 8
229960003563 calcium carbonate Drugs 0.000 claims description 6
235000010216 calcium carbonate Nutrition 0.000 claims description 5
238000001035 drying Methods 0.000 claims description 2
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 108
238000005469 granulation Methods 0.000 description 72
230000003179 granulation Effects 0.000 description 72
239000003826 tablet Substances 0.000 description 72
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 69
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 69
RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 59
239000002245 particle Substances 0.000 description 37
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
238000010992 reflux Methods 0.000 description 29
239000002253 acid Substances 0.000 description 27
239000002775 capsule Substances 0.000 description 26
239000002904 solvent Substances 0.000 description 23
238000003756 stirring Methods 0.000 description 23
238000000634 powder X-ray diffraction Methods 0.000 description 22
239000000243 solution Substances 0.000 description 21
239000011248 coating agent Substances 0.000 description 20
238000004090 dissolution Methods 0.000 description 20
239000000843 powder Substances 0.000 description 20
238000000576 coating method Methods 0.000 description 19
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
239000006185 dispersion Substances 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 13
229940060367 inert ingredients Drugs 0.000 description 13
239000011343 solid material Substances 0.000 description 13
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
238000010438 heat treatment Methods 0.000 description 12
239000008213 purified water Substances 0.000 description 12
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
238000009835 boiling Methods 0.000 description 10
238000001953 recrystallisation Methods 0.000 description 10
239000007903 gelatin capsule Substances 0.000 description 9
239000002002 slurry Substances 0.000 description 9
239000000126 substance Substances 0.000 description 9
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 8
125000001931 aliphatic group Chemical group 0.000 description 8
239000012065 filter cake Substances 0.000 description 8
238000001914 filtration Methods 0.000 description 8
TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical compound COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 description 8
239000000523 sample Substances 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
238000010533 azeotropic distillation Methods 0.000 description 7
239000005453 ketone based solvent Substances 0.000 description 7
238000002844 melting Methods 0.000 description 7
230000008018 melting Effects 0.000 description 7
238000005550 wet granulation Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
239000012296 anti-solvent Substances 0.000 description 6
239000013078 crystal Substances 0.000 description 6
239000003759 ester based solvent Substances 0.000 description 6
239000012458 free base Substances 0.000 description 6
239000011521 glass Substances 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
239000003791 organic solvent mixture Substances 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
239000000739 antihistaminic agent Substances 0.000 description 5
239000007891 compressed tablet Substances 0.000 description 5
238000002425 crystallisation Methods 0.000 description 5
230000008025 crystallization Effects 0.000 description 5
238000000113 differential scanning calorimetry Methods 0.000 description 5
238000004821 distillation Methods 0.000 description 5
XAGIKTXVRKZQRW-UHFFFAOYSA-N ethyl 2-[4-[4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butanoyl]phenyl]-2-methylpropanoate;hydrochloride Chemical compound Cl.C1=CC(C(C)(C)C(=O)OCC)=CC=C1C(=O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 XAGIKTXVRKZQRW-UHFFFAOYSA-N 0.000 description 5
238000009472 formulation Methods 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000000314 lubricant Substances 0.000 description 5
229910052757 nitrogen Inorganic materials 0.000 description 5
229910000033 sodium borohydride Inorganic materials 0.000 description 5
239000012279 sodium borohydride Substances 0.000 description 5
RRJFVPUCXDGFJB-UHFFFAOYSA-N Fexofenadine hydrochloride Chemical compound Cl.C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RRJFVPUCXDGFJB-UHFFFAOYSA-N 0.000 description 4
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
239000007900 aqueous suspension Substances 0.000 description 4
229940124630 bronchodilator Drugs 0.000 description 4
230000000694 effects Effects 0.000 description 4
WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 4
239000001257 hydrogen Substances 0.000 description 4
229910052739 hydrogen Inorganic materials 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 4
229940011051 isopropyl acetate Drugs 0.000 description 4
GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 4
230000008569 process Effects 0.000 description 4
235000012239 silicon dioxide Nutrition 0.000 description 4
229940032147 starch Drugs 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
230000000007 visual effect Effects 0.000 description 4
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
-1 aliphatic nitriles Chemical class 0.000 description 3
229910052782 aluminium Inorganic materials 0.000 description 3
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
230000001387 anti-histamine Effects 0.000 description 3
239000000043 antiallergic agent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008367 deionised water Substances 0.000 description 3
229910021641 deionized water Inorganic materials 0.000 description 3
239000007884 disintegrant Substances 0.000 description 3
238000011049 filling Methods 0.000 description 3
238000000227 grinding Methods 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229940069328 povidone Drugs 0.000 description 3
238000001556 precipitation Methods 0.000 description 3
239000011541 reaction mixture Substances 0.000 description 3
239000000377 silicon dioxide Substances 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
238000003828 vacuum filtration Methods 0.000 description 3
229920003084 Avicel® PH-102 Polymers 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical compound NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 2
229940125715 antihistaminic agent Drugs 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000168 bronchodilator agent Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
239000000850 decongestant Substances 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
WUWWDNWDODGALA-UHFFFAOYSA-N ethyl 2-[4-[4-[4-[hydroxy(diphenyl)methyl]piperidin-1-yl]butanoyl]phenyl]-2-methylpropanoate Chemical compound C1=CC(C(C)(C)C(=O)OCC)=CC=C1C(=O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 WUWWDNWDODGALA-UHFFFAOYSA-N 0.000 description 2
125000004494 ethyl ester group Chemical group 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000007789 gas Substances 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
239000001863 hydroxypropyl cellulose Substances 0.000 description 2
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
150000002576 ketones Chemical class 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
150000007522 mineralic acids Chemical class 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
229940068918 polyethylene glycol 400 Drugs 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
239000011591 potassium Substances 0.000 description 2
238000010791 quenching Methods 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000011877 solvent mixture Substances 0.000 description 2
239000007858 starting material Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
229940127230 sympathomimetic drug Drugs 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
UWYVPFMHMJIBHE-OWOJBTEDSA-N (e)-2-hydroxybut-2-enedioic acid Chemical compound OC(=O)\C=C(\O)C(O)=O UWYVPFMHMJIBHE-OWOJBTEDSA-N 0.000 description 1
BZCOSCNPHJNQBP-UPHRSURJSA-N (z)-2,3-dihydroxybut-2-enedioic acid Chemical compound OC(=O)C(\O)=C(\O)C(O)=O BZCOSCNPHJNQBP-UPHRSURJSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
PKRSYEPBQPFNRB-UHFFFAOYSA-N 2-phenoxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1OC1=CC=CC=C1 PKRSYEPBQPFNRB-UHFFFAOYSA-N 0.000 description 1
WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
ALYNCZNDIQEVRV-PZFLKRBQSA-N 4-amino-3,5-ditritiobenzoic acid Chemical compound [3H]c1cc(cc([3H])c1N)C(O)=O ALYNCZNDIQEVRV-PZFLKRBQSA-N 0.000 description 1
WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
238000004438 BET method Methods 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000282412 Homo Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
OPKOKAMJFNKNAS-UHFFFAOYSA-N N-methylethanolamine Chemical compound CNCCO OPKOKAMJFNKNAS-UHFFFAOYSA-N 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
240000006413 Prunus persica var. persica Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000001342 alkaline earth metals Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960004909 aminosalicylic acid Drugs 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
235000010323 ascorbic acid Nutrition 0.000 description 1
239000011668 ascorbic acid Substances 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
229960004365 benzoic acid Drugs 0.000 description 1
230000037396 body weight Effects 0.000 description 1
FLLNLJJKHKZKMB-UHFFFAOYSA-N boron;tetramethylazanium Chemical compound [B].C[N+](C)(C)C FLLNLJJKHKZKMB-UHFFFAOYSA-N 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
150000005323 carbonate salts Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003093 cationic surfactant Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000010411 cooking Methods 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
150000004683 dihydrates Chemical class 0.000 description 1
239000008298 dragée Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
239000010419 fine particle Substances 0.000 description 1
239000011888 foil Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
239000005457 ice water Substances 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
235000001055 magnesium Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
229910052753 mercury Inorganic materials 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229960000540 polacrilin potassium Drugs 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
WVWZXTJUCNEUAE-UHFFFAOYSA-M potassium;1,2-bis(ethenyl)benzene;2-methylprop-2-enoate Chemical compound [K+].CC(=C)C([O-])=O.C=CC1=CC=CC=C1C=C WVWZXTJUCNEUAE-UHFFFAOYSA-M 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000003825 pressing Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
238000010926 purge Methods 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
239000010453 quartz Substances 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000009466 transformation Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pulmonology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Hydrogenated Pyridines (AREA)

NO19973938A 1995-02-28 1997-08-27 Farmasoytisk preparat i fast enhetsdoseringsform NO325760B1 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US39595295A	1995-02-28	1995-02-28
US55228795A	1995-12-12	1995-12-12
PCT/US1996/001253 WO1996026726A1 (en)	1995-02-28	1996-01-26	Pharmaceutical composition for piperidinoalkanol compounds

Publications (3)

Publication Number	Publication Date
NO973938D0 NO973938D0 (no)	1997-08-27
NO973938L NO973938L (no)	1997-10-28
NO325760B1 true NO325760B1 (no)	2008-07-14

Family

ID=27015322

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO19973938A NO325760B1 (no)	1995-02-28	1997-08-27	Farmasoytisk preparat i fast enhetsdoseringsform
NO20065390A NO20065390L (no)	1995-02-28	2006-11-23	Farmasoytisk preparat i fast enhetsdoseringsform

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO20065390A NO20065390L (no)	1995-02-28	2006-11-23	Farmasoytisk preparat i fast enhetsdoseringsform

Country Status (22)

Country	Link
US (9)	US5738872A (zh)
EP (1)	EP0812195B1 (zh)
JP (3)	JP4105762B2 (zh)
KR (1)	KR100405116B1 (zh)
CN (1)	CN1090935C (zh)
AR (1)	AR003929A1 (zh)
AT (1)	ATE226819T1 (zh)
AU (1)	AU701042B2 (zh)
CA (1)	CA2213700C (zh)
CL (1)	CL2004000317A1 (zh)
DE (1)	DE69624559T2 (zh)
DK (1)	DK0812195T3 (zh)
ES (1)	ES2181868T3 (zh)
FI (1)	FI973518A (zh)
HU (1)	HUP9802086A3 (zh)
IL (1)	IL117237A (zh)
MX (1)	MX9706449A (zh)
NO (2)	NO325760B1 (zh)
NZ (1)	NZ302926A (zh)
PT (1)	PT812195E (zh)
TW (1)	TW460284B (zh)
WO (1)	WO1996026726A1 (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030045722A1 (en) *	1994-05-18	2003-03-06	Henton Daniel R.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2585705C (en) *	1994-05-18	2012-04-17	Aventis Pharmaceuticals Inc.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
ES2181868T3 (es) *	1995-02-28	2003-03-01	Aventis Pharma Inc	Composicion farmaceutica para compuestos de piperidinoalcanol.
US7091183B1 (en) *	1996-12-03	2006-08-15	Boston Medical Center Corporation	Specific antagonists for glucose-dependent insulinotropic polypeptide (GIP)
CZ295461B6 (cs) *	1997-08-26	2005-08-17	Aventis Pharmaceuticals Inc.	Farmaceutický prostředek ve formě dvouvrstvé tablety
US6129932A (en) *	1997-09-05	2000-10-10	Merck & Co., Inc.	Compositions for inhibiting platelet aggregation
CA2300452C (en) *	1997-12-22	2000-11-28	Schering Corporation	Orally administrable solid ribavirin dosage forms and process for making them
US5914128A (en) *	1997-12-22	1999-06-22	Schering Corporation	Orally administrable solid dosage form
US5916594A (en) *	1997-12-22	1999-06-29	Schering Corporation	Process of making solid ribavirin dosage forms
IL157539A0 (en) *	2000-02-17	2004-03-28	Teva Pharma	A stable pharmaceutical formulation comprising torsemide modification ii
US6613906B1 (en)	2000-06-06	2003-09-02	Geneva Pharmaceuticals, Inc.	Crystal modification
US8155096B1 (en)	2000-12-01	2012-04-10	Ipr Licensing Inc.	Antenna control system and method
US20030022921A1 (en) *	2001-02-21	2003-01-30	Minutza Leibovici	Stable pharmaceutical formulation comprising torsemide modification II
US6569454B2 (en) *	2001-02-27	2003-05-27	Minh Van Nguyen	Simple tablet compression using gelatin
KR20040012747A (ko) *	2001-04-09	2004-02-11	테바 파마슈티컬 인더스트리즈 리미티드	펙소페나딘 염산염의 다형체
US20030021849A1 (en) *	2001-04-09	2003-01-30	Ben-Zion Dolitzky	Polymorphs of fexofenadine hydrochloride
ES2301662T3 (es) *	2001-07-31	2008-07-01	Texcontor Etablissement	Polimorfo de clorhidrato de fexofenadina.
US6723348B2 (en) *	2001-11-16	2004-04-20	Ethypharm	Orodispersible tablets containing fexofenadine
PE20030762A1 (es)	2001-12-18	2003-09-05	Schering Corp	Compuestos heterociclicos como antagonistas nk1
GB0201508D0 (en) *	2002-01-23	2002-03-13	Novartis Ag	Organic compounds
CA2477088A1 (en)	2002-02-22	2003-10-02	New River Pharmaceuticals Inc.	Active agent delivery systems and methods for protecting and administering active agents
WO2003092654A1 (en) *	2002-05-02	2003-11-13	President And Fellows Of Harvard College	Formulations limiting spread of pulmonary infections
US7393862B2 (en) *	2002-05-17	2008-07-01	Celgene Corporation	Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
USRE48890E1 (en)	2002-05-17	2022-01-11	Celgene Corporation	Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
US7968569B2 (en) *	2002-05-17	2011-06-28	Celgene Corporation	Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US20040044038A1 (en) *	2002-06-10	2004-03-04	Barnaba Krochmal	Polymorphic form XVI of fexofenadine hydrochloride
CA2477221A1 (en) *	2003-01-03	2004-07-29	Minh Nguyen	Simple tablet compression using gelatin
US6869963B2 (en) *	2003-07-11	2005-03-22	Sandoz Ag	Stable pharmaceutical compositions containing an ACE inhibitor
US20050065183A1 (en) *	2003-07-31	2005-03-24	Indranil Nandi	Fexofenadine composition and process for preparing
US20050220877A1 (en) *	2004-03-31	2005-10-06	Patel Ashish A	Bilayer tablet comprising an antihistamine and a decongestant
EP1628959A2 (en) *	2004-04-26	2006-03-01	Teva Pharmaceutical Industries Ltd	Crystalline forms of fexofenadine hydrochloride and processes for their preparation
JP2008514641A (ja) *	2004-09-28	2008-05-08	テバファーマシューティカルインダストリーズリミティド	結晶形フェキソフェナジン、およびその調製方法
US8367105B2 (en)	2004-11-10	2013-02-05	Teva Pharmaceutical Industries, Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
CA2587295A1 (en) *	2004-11-10	2006-05-18	Teva Pharmaceutical Industries Ltd.	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
KR101380088B1 (ko)	2005-05-26	2014-04-10	다이닛본 스미토모 세이야꾸 가부시끼가이샤	약학 조성물
KR100735904B1 (ko)	2005-08-02	2007-07-04	주식회사 드림파마	한방 건조엑스 함유 정제 조성물 및 그를 이용한 한방건조엑스 함유 정제의 제조방법
WO2007020079A2 (en) *	2005-08-17	2007-02-22	Synthon B.V.	Orally disintegratable simvastatin tablets
WO2007052310A2 (en) *	2005-11-03	2007-05-10	Morepen Laboratories Limited	Polymorphs of fexofenadine hydrochloride and process for their preparation
CL2007000945A1 (es)	2006-04-05	2008-01-25	Schering Corp	Formulacion farmaceutica que comprende una sal cristalina de monohidrato de hidrocloruro de (5s,8s)-8-[[(1r)-1-(3,5-bistrifluorometil)fenil]-etoximetil]-8-fenil-1,7-diaza-espiro[4.5]decan-2-ona; capsula que la contiene; y uso en el tratamiento de la emesis y nausea.
JP5452236B2 (ja) *	2007-03-02	2014-03-26	ファーナム・カンパニーズ・インコーポレーテッド	ロウ様物質を用いた徐放性組成物
AR065802A1 (es)	2007-03-22	2009-07-01	Schering Corp	Formulaciones de comprimidos que contienen sales de 8- [( 1- ( 3,5- bis- (trifluorometil) fenil) -etoxi ) - metil) -8- fenil -1, 7- diaza- spiro [ 4,5] decan -2- ona y comprimidos elaborados a partir de estas
US20090076080A1 (en) *	2007-09-19	2009-03-19	Protia, Llc	Deuterium-enriched fexofenadine
EP2437845A1 (en) *	2009-06-05	2012-04-11	Entrigue Surgical, Inc.	Systems and devices for providing therapy of an anatomical structure
KR101834577B1 (ko)	2009-08-14	2018-03-05	옵코 헬스, 인크.	뉴로키닌-1 길항제의 정맥내 제형
FR2959130A1 (fr)	2010-04-21	2011-10-28	Sanofi Aventis	Procede de preparation de compositions pharmaceutiques destinees a l'administration par voie orale comprenant un ou plusieurs principes actifs et les compositions les comprenant.
FR2999937B1 (fr)	2012-12-21	2015-01-09	Sanofi Sa	Unite solide a haute teneur en fexofenadine et son procede de preparation
AR094761A1 (es)	2013-02-14	2015-08-26	Sanofi Sa	Composición farmacéutica para administración oral que comprende fexofenadina y proceso para preparar la misma
EP3016635A1 (en)	2013-07-01	2016-05-11	Aventisub LLC	Liquid pharmaceutical composition for oral administration comprising fexofenadine
US10058542B1 (en)	2014-09-12	2018-08-28	Thioredoxin Systems Ab	Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith
EP3002005A1 (en) *	2014-09-30	2016-04-06	Molkerei Meggle Wasserburg GmbH & Co. Kg	Direct compression excipient based on lactose, cellulose and starch
KR101825041B1 (ko) *	2016-04-07	2018-02-02	주식회사 바이오솔루션	물질 p를 포함하는 상처치유용 약학 조성물

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3806526A (en) *	1972-01-28	1974-04-23	Richardson Merrell Inc	1-aroylalkyl-4-diphenylmethyl piperidines
US3878217A (en) *	1972-01-28	1975-04-15	Richardson Merrell Inc	Alpha-aryl-4-substituted piperidinoalkanol derivatives
DE2348334C2 (de) *	1973-09-26	1982-11-11	Boehringer Mannheim Gmbh, 6800 Mannheim	Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) *	1973-09-26	1977-11-29	Boehringer Mannheim G.M.B.H.	Rapidly resorbable glibenclamide
US3966949A (en) *	1973-10-12	1976-06-29	Richardson-Merrell Inc.	Pharmaceutical compositions and preparing same
US3941795A (en) *	1974-02-08	1976-03-02	Richardson-Merrell Inc.	α-ARYL-4-SUBSTITUTED PIPERIDINOALKANOL DERIVATIVES
FR2408345A1 (fr) *	1976-11-30	1979-06-08	Besins Jean Louis	Nouvelle composition a action anti-conceptionnelle
US4285957A (en) *	1979-04-10	1981-08-25	Richardson-Merrell Inc.	1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4254130A (en) *	1979-04-10	1981-03-03	Richardson-Merrell Inc.	Piperidine derivatives
US4285958A (en) *	1979-04-10	1981-08-25	Richardson-Merrell Inc.	1-Piperidine-alkylene ketones, pharmaceutical compositions thereof and method of use thereof
US4254129A (en) *	1979-04-10	1981-03-03	Richardson-Merrell Inc.	Piperidine derivatives
US4493528A (en) *	1980-04-11	1985-01-15	Board Of Trustees Of The Leland Stanford Junior University	Fiber optic directional coupler
EP0111114A3 (de) *	1982-11-06	1985-10-09	Telefonbau und Normalzeit GmbH	Schaltungsanordnung für eine Fernsprechvermittlungsanlage, insbesondere Fernsprechnebenstellenanlage mit zusätzlichem Datenverkehr
GB8613811D0 (en) *	1986-06-06	1986-07-09	Phares Pharm Res Nv	Composition & method
US4609675A (en) *	1984-08-17	1986-09-02	The Upjohn Company	Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
DK164642C (da) *	1984-08-30	1992-12-14	Merrell Dow Pharma	Farmaceutisk middel indeholdende terfenadin i form af en varmsmelte paafyldt paa kapsler
US4639458A (en) *	1985-01-22	1987-01-27	Merck & Co., Inc.	Tablet and formulation
US4916163A (en) *	1985-06-04	1990-04-10	The Upjohn Company	Spray-dried lactose formulation of micronized glyburide
SE457326B (sv) *	1986-02-14	1988-12-19	Lejus Medical Ab	Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
US4963540A (en) *	1986-04-16	1990-10-16	Maxson Wayne S	Method for treatment of premenstrual syndrome
SE8603812D0 (sv) *	1986-09-12	1986-09-12	Draco Ab	Administration of liposomes to mammals
DE3720493A1 (de) *	1987-06-20	1989-01-26	Nattermann A & Cie	Arzneizubereitungen mit mikronisierten ebselen-kristallen
US4929605A (en) *	1987-10-07	1990-05-29	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol derivatives
CN1053570C (zh) *	1987-10-07	2000-06-21	默尔多药物公司	哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4996061A (en) *	1987-10-07	1991-02-26	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical composition for piperidinoalkanol-decongestant combination
AR240018A1 (es) *	1987-10-07	1990-01-31	Merrell Pharma Inc	Procedimiento para preparar una composicion que comprende derivados de piperidinoalcanol.
US5030447A (en)	1988-03-31	1991-07-09	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions having good stability
US4999226A (en) *	1988-06-01	1991-03-12	Merrell Dow Pharmaceuticals Inc.	Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
SE8804173A0 (sv) *	1988-11-18	1990-05-19	Lim Johan Ab	Insektsfångare
AR245888A1 (es)	1989-01-23	1994-03-30	Merrell Pharma Inc	Procedimiento para la preparacion de una composicion farmaceutica liquida de derivados de piperidinoalcanol.
US4990535A (en) *	1989-05-03	1991-02-05	Schering Corporation	Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5376386A (en) *	1990-01-24	1994-12-27	British Technology Group Limited	Aerosol carriers
IT1246188B (it) *	1990-07-27	1994-11-16	Resa Farma	Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5271944A (en) *	1991-04-05	1993-12-21	Biofor, Ltd.	Pharmacologically enhanced formulations
SE9101090D0 (sv) *	1991-04-11	1991-04-11	Astra Ab	Process for conditioning of water-soluble substances
IT1250421B (it) *	1991-05-30	1995-04-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
US5169638A (en) *	1991-10-23	1992-12-08	E. R. Squibb & Sons, Inc.	Buoyant controlled release powder formulation
US5516803A (en) *	1991-10-30	1996-05-14	Mcneilab, Inc.	Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug
ATE171865T1 (de) *	1991-12-12	1998-10-15	Glaxo Group Ltd	Arzneimittel
US5301664A (en) *	1992-03-06	1994-04-12	Sievers Robert E	Methods and apparatus for drug delivery using supercritical solutions
DK0635004T3 (da)	1992-04-10	2002-11-11	Merrell Pharma Inc	4-Diphenylmethylpiperidinderivater og fremgangsmåde til fremstilling deraf
ES2121084T3 (es)	1992-05-11	2002-02-16	Merrell Pharma Inc	Utilizacion de derivados de terfenadina como antihistaminicos en un paciente que padece de trastornos hepaticos.
US5429825A (en) *	1992-06-26	1995-07-04	Mcneil-Ppc, Inc.	Rotomelt granulation
CA2141572C (en) *	1992-08-03	2001-02-06	James W. Young	Terfenadine metabolites and their optically pure isomers for treating allergic disorders
US5474757A (en) *	1992-10-16	1995-12-12	Rutgers University	Prevention of acetaminophen overdose toxicity with organosulfur compounds
US5314697A (en) *	1992-10-23	1994-05-24	Schering Corporation	Stable extended release oral dosage composition comprising loratadine and pseudoephedrine
SE9203743D0 (sv) *	1992-12-11	1992-12-11	Astra Ab	Efficient use
IT1264517B1 (it) *	1993-05-31	1996-09-24	Ekita Investments Nv	Compressa farmaceutica atta al rilascio in tempi successivi dei principi attivi in essa veicolati
EP0703902B1 (en) *	1993-06-24	1998-12-16	Albany Molecular Research, Inc.	Process for the production of piperidine derivatives
IT1264696B1 (it) *	1993-07-09	1996-10-04	Applied Pharma Res	Forme farmaceutiche destinate alla somministrazione orale in grado di rilasciare sostanze attive a velocita' controllata e differenziata
CA2128820A1 (en) *	1993-07-27	1995-01-28	Walter G. Gowan, Jr.	Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
CA2128821A1 (en) *	1993-07-27	1995-01-28	Dilip J. Gole	Freeze-dried pharmaceutical dosage form and process for separation thereof
US5895664A (en) *	1993-09-10	1999-04-20	Fuisz Technologies Ltd.	Process for forming quickly dispersing comestible unit and product therefrom
WO1995010278A1 (en) *	1993-10-15	1995-04-20	Hoechst Marion Roussel, Inc.	Treatment of allergic disorders with terfenadine carboxylate
US5451409A (en) *	1993-11-22	1995-09-19	Rencher; William F.	Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5478858A (en) *	1993-12-17	1995-12-26	The Procter & Gamble Company	5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5458879A (en) *	1994-03-03	1995-10-17	The Procter & Gamble Company	Oral vehicle compositions
US20030045722A1 (en)	1994-05-18	2003-03-06	Henton Daniel R.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
CA2585705C (en) *	1994-05-18	2012-04-17	Aventis Pharmaceuticals Inc.	Processes for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
US5567439A (en) *	1994-06-14	1996-10-22	Fuisz Technologies Ltd.	Delivery of controlled-release systems(s)
ES2181868T3 (es) *	1995-02-28	2003-03-01	Aventis Pharma Inc	Composicion farmaceutica para compuestos de piperidinoalcanol.
US5574045A (en) *	1995-06-06	1996-11-12	Hoechst Marion Roussel, Inc.	Oral pharmaceutical composition of piperidinoalkanol compounds in solution form
DE19720312A1 (de) *	1997-05-15	1998-11-19	Hoechst Ag	Zubereitung mit erhöhter in vivo Verträglichkeit
EP1003528B1 (en) *	1997-08-14	2002-09-25	Aventis Pharmaceuticals Inc.	Method of enhancing bioavailability of fexofenadine and its derivatives
US6451815B1 (en)	1997-08-14	2002-09-17	Aventis Pharmaceuticals Inc.	Method of enhancing bioavailability of fexofenadine and its derivatives
CZ295461B6 (cs) *	1997-08-26	2005-08-17	Aventis Pharmaceuticals Inc.	Farmaceutický prostředek ve formě dvouvrstvé tablety

1996
- 1996-01-26 ES ES96905292T patent/ES2181868T3/es not_active Expired - Lifetime
- 1996-01-26 EP EP96905292A patent/EP0812195B1/en not_active Revoked
- 1996-01-26 AU AU49098/96A patent/AU701042B2/en not_active Expired
- 1996-01-26 JP JP52625796A patent/JP4105762B2/ja not_active Expired - Lifetime
- 1996-01-26 DE DE69624559T patent/DE69624559T2/de not_active Revoked
- 1996-01-26 HU HU9802086A patent/HUP9802086A3/hu unknown
- 1996-01-26 KR KR1019970705981A patent/KR100405116B1/ko not_active IP Right Cessation
- 1996-01-26 AT AT96905292T patent/ATE226819T1/de not_active IP Right Cessation
- 1996-01-26 DK DK96905292T patent/DK0812195T3/da active
- 1996-01-26 CA CA002213700A patent/CA2213700C/en not_active Expired - Lifetime
- 1996-01-26 MX MX9706449A patent/MX9706449A/es unknown
- 1996-01-26 CN CN96192200A patent/CN1090935C/zh not_active Expired - Lifetime
- 1996-01-26 PT PT96905292T patent/PT812195E/pt unknown
- 1996-01-26 NZ NZ302926A patent/NZ302926A/xx not_active IP Right Cessation
- 1996-01-26 WO PCT/US1996/001253 patent/WO1996026726A1/en active IP Right Grant
- 1996-02-23 TW TW085102075A patent/TW460284B/zh not_active IP Right Cessation
- 1996-02-23 IL IL11723796A patent/IL117237A/xx not_active IP Right Cessation
- 1996-02-27 AR ARP960101530A patent/AR003929A1/es not_active Application Discontinuation
- 1996-11-01 US US08/742,166 patent/US5738872A/en not_active Expired - Lifetime
1997
- 1997-08-27 NO NO19973938A patent/NO325760B1/no not_active IP Right Cessation
- 1997-08-27 FI FI973518A patent/FI973518A/fi not_active Application Discontinuation
- 1997-10-03 US US08/943,460 patent/US5855912A/en not_active Expired - Lifetime
- 1997-10-09 US US08/948,005 patent/US5932247A/en not_active Expired - Lifetime
1998
- 1998-09-21 US US09/157,841 patent/US6113942A/en not_active Expired - Lifetime
2001
- 2001-04-30 US US09/845,966 patent/US20010022973A1/en not_active Abandoned
2002
- 2002-01-04 US US10/039,798 patent/US20020106405A1/en not_active Abandoned
2003
- 2003-01-21 US US10/347,953 patent/US20030203020A1/en not_active Abandoned
2004
- 2004-02-20 CL CL200400317A patent/CL2004000317A1/es unknown
- 2004-06-09 JP JP2004170680A patent/JP4177787B2/ja not_active Expired - Lifetime
2006
- 2006-11-23 NO NO20065390A patent/NO20065390L/no not_active Application Discontinuation
2007
- 2007-04-26 US US11/740,655 patent/US20070249671A1/en not_active Abandoned
2008
- 2008-06-11 JP JP2008152525A patent/JP2008266347A/ja active Pending
2009
- 2009-09-23 US US12/565,410 patent/US8129408B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
NO973938D0 (no)	1997-08-27
CA2213700C (en)	2002-04-02
JP2004292459A (ja)	2004-10-21
HUP9802086A2 (hu)	1999-01-28
TW460284B (en)	2001-10-21
AU4909896A (en)	1996-09-18
PT812195E (pt)	2003-03-31
US20010022973A1 (en)	2001-09-20
JP4177787B2 (ja)	2008-11-05
CL2004000317A1 (es)	2005-01-21
US6113942A (en)	2000-09-05
EP0812195A1 (en)	1997-12-17
DE69624559T2 (de)	2003-07-10
AU701042B2 (en)	1999-01-21
CN1090935C (zh)	2002-09-18
FI973518A0 (fi)	1997-08-27
ATE226819T1 (de)	2002-11-15
DE69624559D1 (de)	2002-12-05
JP2008266347A (ja)	2008-11-06
KR19980702575A (ko)	1998-07-15
ES2181868T3 (es)	2003-03-01
NZ302926A (en)	1998-10-28
CA2213700A1 (en)	1996-09-06
EP0812195B1 (en)	2002-10-30
US5855912A (en)	1999-01-05
AR003929A1 (es)	1998-09-30
US20070249671A1 (en)	2007-10-25
US20030203020A1 (en)	2003-10-30
KR100405116B1 (ko)	2004-02-05
MX9706449A (es)	1997-11-29
FI973518A (fi)	1997-08-27
NO20065390L (no)	1997-10-28
IL117237A0 (en)	1996-06-18
HUP9802086A3 (en)	2001-02-28
JP4105762B2 (ja)	2008-06-25
IL117237A (en)	2001-01-11
US20100021547A1 (en)	2010-01-28
US8129408B2 (en)	2012-03-06
US20020106405A1 (en)	2002-08-08
CN1176599A (zh)	1998-03-18
NO973938L (no)	1997-10-28
DK0812195T3 (da)	2003-03-03
WO1996026726A1 (en)	1996-09-06
US5738872A (en)	1998-04-14
US5932247A (en)	1999-08-03
JPH11501028A (ja)	1999-01-26

Publication	Publication Date	Title
NO325760B1 (no)	2008-07-14	Farmasoytisk preparat i fast enhetsdoseringsform
US7666881B2 (en)	2010-02-23	Methods of treating allergic reactions using hydrated forms of antihistaminic piperidine derivatives
IL134772A (en)	2002-02-10	Pharmaceutical compositions of piperidinoalkanol compounds in solid unit dosage form

Legal Events

Date	Code	Title	Description
2016-02-08	MK1K	Patent expired